167 related articles for article (PubMed ID: 29509940)
1. Multiplexed immunofluorescence reveals potential PD-1/PD-L1 pathway vulnerabilities in craniopharyngioma.
Coy S; Rashid R; Lin JR; Du Z; Donson AM; Hankinson TC; Foreman NK; Manley PE; Kieran MW; Reardon DA; Sorger PK; Santagata S
Neuro Oncol; 2018 Jul; 20(8):1101-1112. PubMed ID: 29509940
[TBL] [Abstract][Full Text] [Related]
2. Expression of programmed death-ligand 1 (PD-L1) in human pituitary neuroendocrine tumor.
Suteau V; Collin A; Menei P; Rodien P; Rousselet MC; Briet C
Cancer Immunol Immunother; 2020 Oct; 69(10):2053-2061. PubMed ID: 32445029
[TBL] [Abstract][Full Text] [Related]
3. Multi-omics analysis of adamantinomatous craniopharyngiomas reveals distinct molecular subgroups with prognostic and treatment response significance.
Wang X; Zhao C; Lin J; Liu H; Zeng Q; Chen H; Wang Y; Xu D; Chen W; Xu M; Zhang E; Lin D; Lin Z
Chin Med J (Engl); 2024 Apr; 137(7):859-870. PubMed ID: 37565822
[TBL] [Abstract][Full Text] [Related]
4. Unraveling the complexity of the senescence-associated secretory phenotype in adamantinomatous craniopharyngioma using multimodal machine learning analysis.
Prince EW; Apps JR; Jeang J; Chee K; Medlin S; Jackson EM; Dudley R; Limbrick D; Naftel R; Johnston J; Feldstein N; Prolo LM; Ginn K; Niazi T; Smith A; Kilburn L; Chern J; Leonard J; Lam S; Hersh DS; Gonzalez-Meljem JM; Amani V; Donson AM; Mitra SS; Bandopadhayay P; Martinez-Barbera JP; Hankinson TC
Neuro Oncol; 2024 Jun; 26(6):1109-1123. PubMed ID: 38334125
[TBL] [Abstract][Full Text] [Related]
5. [Craniopharyngiomas: The Dawn of a New Era with the Elucidation of Driver Genes].
Fujio S; Hanaya R
No Shinkei Geka; 2023 Sep; 51(5):917-928. PubMed ID: 37743344
[TBL] [Abstract][Full Text] [Related]
6. Axl as a potential therapeutic target for adamantinomatous craniopharyngiomas: Based on single nucleus RNA-seq and spatial transcriptome profiling.
Chen Y; Liu X; Ainiwan Y; Li M; Pan J; Chen Y; Xiao Z; Wang Z; Xiao X; Tang J; Zeng G; Liang J; Su X; Kungulli R; Fan Y; Lin Q; Liya A; Zheng Y; Chen Z; Xu C; Zhang H; Chen G
Cancer Lett; 2024 Jun; 592():216905. PubMed ID: 38677641
[TBL] [Abstract][Full Text] [Related]
7. Correlations between the expression of molecules in the TGF-β signaling pathway and clinical factors in adamantinomatous craniopharyngiomas.
Jin L; Cai K; Wu W; Xiao Y; Qiao N; Liu F; Ru S; Cao L; Zhu H; Bai J; Liu C; Li C; Zhao P; Zhang Y; Gui S
Front Endocrinol (Lausanne); 2023; 14():1167776. PubMed ID: 37854185
[TBL] [Abstract][Full Text] [Related]
8. Advances in the treatment of Adamantinomatous craniopharyngioma: How to balance tumor control and quality of life in the current environment: a narrative review.
Chen A; Ai M; Sun T
Front Oncol; 2023; 13():1326595. PubMed ID: 38188294
[TBL] [Abstract][Full Text] [Related]
9. Comparison of central diabetes insipidus (antidiuretic hormone deficiency) and stalk effect in patients with adamantinomatous and papillary craniopharyngioma.
Feng Y; Zhong L
Acta Neurol Belg; 2024 Apr; ():. PubMed ID: 38669000
[TBL] [Abstract][Full Text] [Related]
10. First evidence of anti-VEGF efficacy in an adult case of adamantinomatous craniopharyngioma: Case report and illustrative review.
De Rosa A; Calvanese F; Ducray F; Vasiljevic A; Manet R; Raverot G; Jouanneau E
Ann Endocrinol (Paris); 2023 Dec; 84(6):727-733. PubMed ID: 37865272
[TBL] [Abstract][Full Text] [Related]
11. Adamantinomatous Craniopharyngioma in an Adult: A Case Report with NGS Analysis.
Jastania RA; Saeed M; Al-Khalidi H; AlQuthami K; Nageeti TH; Al-Allaf FA; Valerie K; Taher MM
Int Med Case Rep J; 2020; 13():123-137. PubMed ID: 32368160
[TBL] [Abstract][Full Text] [Related]
12. Proteomics study of primary and recurrent adamantinomatous craniopharyngiomas.
Deng H; Lei T; Liu S; Hao W; Hu M; Xiang X; Ye L; Chen D; Li Y; Liu F
Clin Proteomics; 2024 Apr; 21(1):29. PubMed ID: 38594611
[TBL] [Abstract][Full Text] [Related]
13. Meta-analysis of the correlation between glioma prognosis and PD-1/PD-L1 expression.
Ren CC; Xu B; Wang MS; He F; Chen JH; Liao L; Liang W
Asian J Surg; 2023 Dec; 46(12):5632-5634. PubMed ID: 37625958
[No Abstract] [Full Text] [Related]
14. Identification of tumor stem-like cells in admanatimomatous craniopharyngioma and determination of these cells' pathological significance.
Wang CH; Qi ST; Fan J; Pan J; Peng JX; Nie J; Bao Y; Liu YW; Zhang X; Liu Y
J Neurosurg; 2019 Aug; 133(3):664-674. PubMed ID: 31470408
[TBL] [Abstract][Full Text] [Related]
15. Targeted therapy in BRAF mutated aggressive papillary craniopharyngioma: a case report and overview of the literature.
Losa M; Mazza E; Pedone E; Nocera G; Liscia N; Reni M; Mortini P
J Endocrinol Invest; 2024 May; ():. PubMed ID: 38696125
[TBL] [Abstract][Full Text] [Related]
16. Analysis of KLRB1-mediated immunosuppressive regulation in adamantinomatous craniopharyngioma.
Wei W
J Neurol Surg A Cent Eur Neurosurg; 2024 Apr; ():. PubMed ID: 38657676
[TBL] [Abstract][Full Text] [Related]
17. The role of PD-L1 expression in pituitary tumours: lessons from the current literature.
Lopes-Pinto M; Lacerda-Nobre E; Silva AL; Tortosa F; Marques P
Neuroendocrinology; 2024 May; ():. PubMed ID: 38754394
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic control of adamantinomatous craniopharyngiomas.
Marrero-Gutiérrez J; Bueno AC; Martins CS; Coeli-Lacchini FB; Silva-Júnior RMP; Marques Gonçalves GH; Ozaki JGO; de Almeida E Silva DC; Wildemberg LE; da Silva Antunes XL; Dos Santos AC; Machado HR; Santos MV; Moreira AC; Gadelha MR; Vêncio RZN; Antonini SRR; de Castro M
J Clin Endocrinol Metab; 2024 Jan; ():. PubMed ID: 38181427
[TBL] [Abstract][Full Text] [Related]
19. Highly multiplexed immunofluorescence imaging of human tissues and tumors using t-CyCIF and conventional optical microscopes.
Lin JR; Izar B; Wang S; Yapp C; Mei S; Shah PM; Santagata S; Sorger PK
Elife; 2018 Jul; 7():. PubMed ID: 29993362
[TBL] [Abstract][Full Text] [Related]
20. Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPK/ERK pathway as a novel therapeutic target.
Apps JR; Carreno G; Gonzalez-Meljem JM; Haston S; Guiho R; Cooper JE; Manshaei S; Jani N; Hölsken A; Pettorini B; Beynon RJ; Simpson DM; Fraser HC; Hong Y; Hallang S; Stone TJ; Virasami A; Donson AM; Jones D; Aquilina K; Spoudeas H; Joshi AR; Grundy R; Storer LCD; Korbonits M; Hilton DA; Tossell K; Thavaraj S; Ungless MA; Gil J; Buslei R; Hankinson T; Hargrave D; Goding C; Andoniadou CL; Brogan P; Jacques TS; Williams HJ; Martinez-Barbera JP
Acta Neuropathol; 2018 May; 135(5):757-777. PubMed ID: 29541918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
